Urine Immunocytology as a Noninvasive Diagnostic Tool for Acute Kidney Rejection: a Single Center Experience by Karlo Mihovilović et al.
Coll. Antropol. 34 (2010) 1: 63–67
Original scientific paper
Urine Immunocytology as a Noninvasive
Diagnostic Tool for Acute Kidney Rejection:
a Single Center Experience
Karlo Mihovilovi}1, Ika Kardum-Skelin2,5, Danica Ljubanovi}3,5, Mirjana Sabljar-Matovinovi}1,5,
@eljko Vidas4 and Mladen Knotek1,5
1 Department of Medicine, University Hospital »Merkur«, Zagreb, Croatia
2 Laboratory for Cytology and Hematology, University Hospital »Merkur«, Zagreb, Croatia
3 Department of Pathology, University Hospital Dubrava, Zagreb, Croatia
4 Division of Urology, University Hospital »Merkur«, Zagreb, Croatia
5 University of Zagreb, School of Medicine, Zagreb, Croatia
A B S T R A C T
Renal biopsy is a gold standard for establishing diagnosis of acute rejection of the renal allograft. However, being in-
vasive, renal biopsy has potential significant complications and contraindications. Therefore, possibility to noninva-
sively diagnose acute rejection would improve follow-up of kidney transplant patients. The purpose of this study was to
evaluate urine immunocytology for T cells as a method for noninvasive identification of patients with acute renal allo-
graft rejection in comparison to renal biopsy. In this prospective study a cohort of 56 kidney, or kidney-pancreas trans-
plant recipients was included. Patients either received their transplant at the University Hospital »Merkur«, or have been
followed at the »Merkur« Hospital. Patients were subject to either protocol or indication kidney biopsy (a total of 70 biop-
sies), with simultaneous urine immunocytology (determination of CD3-positive cells in the urine sediment). Acute rejec-
tion was diagnosed in 24 biopsies. 23 episodes were T-cell mediated (6 grade IA, 5 grade IB, 1 grade IIA, 1 grade III and
10 borderline), while in 1 case acute humoral rejection was diagnosed. 46 biopsies did not demonstrate acute rejection.
CD3-positive cells were found in 21% of cases with acute rejection and in 13% of cases without rejection (n.s.). A finding
of CD3-positive cells in urine had a sensitivity of 21% and specificity of 87% for acute rejection (including borderline),
with positive predictive value of 45% and negative predictive value of 68%. Although tubulitis is a hallmark of acute T
cell-mediated rejection, detection of T cells in urine sediment was insufficiently sensitive and insufficiently specific for
diagnosing acute rejection in our cohort of kidney transplant recipients.
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Introduction
Kidney transplantation is a standard replacement
therapy for end stage kidney disease, with approximately
150 kidneys annually transplanted in Croatia1. Despite
modern immunosuppressive therapy, acute rejection
(AR) still remains an important problem. In the first
year after kidney transplantation incidence of AR is
10–15%2. Unrecognized and untreated AR adversely im-
pacts graft function and graft survival2; therefore it is of
paramount importance to recognize AR and start treat-
ment early and adequately.
Detection of AR is presently based on monitoring se-
rum creatinine with kidney biopsy as a gold standard.
However, serum creatinine is an insufficiently sensitive
and late indicator of kidney function, because glomerular
filtration rate (GFR) can decline more than 50% without
significant changes in concentration of the serum crea-
tinine3. Unfortunately, percutaneous renal biopsy under
ultrasound guidance, although very sensitive and specific
for diagnosis of renal pathology, is invasive procedure
and therefore has some contraindications and side ef-
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fects. In addition, although quite safe, it is associated
with somemorbidity and even graft loss.2,4 Another prob-
lems associated with renal pathohistology are focality of
AR, with consequent sampling error, and interpatho-
logist variation in interpretation of pathohistology.5,6
Therefore, investigators have been searching for bio-
markers that would be noninvasive and highly sensitive
and specific for diagnosis of AR. Many molecules, from
blood and urine, that reflect activation of the immune
system, have been proposed and evaluated as potential
biomarkers for AR.7–10 Immunocytological staining of
urinary sediment has also been evaluated as a method
for detection of AR in transplant patients in several stud-
ies.7,11,12 In some of these studies high sensitivity and
specificity of immunocytological staining for CD3-posi-
tive cells for AR was reported.7,11
The aim of the present study was to evaluate our ex-
perience in using urine immunocytology for diagnosing
AR in kidney transplant patients.
Participants and Methods
Patients
This study is a part of the prospective, single center
study on immune monitoring of the kidney transplant
recipients at the University Hospital »Merkur«, Zagreb,
Croatia. The study was approved by the University Hos-
pital »Merkur« ethical committee, and patients gave
their consent. For the present analysis we included 56 re-
nal transplant patients who had renal biopsy in parallel
with urine immunocytology. Biopsy and urine cytology
were performed either per protocol (1, 3 and 6 months
post transplant), or for cause, in case of not otherwise ex-
plained impairment of graft function. One patient could
have more than one analysis. Therefore, number of urine
cytology analyses and renal biopsies (70) is greater than
the number of patients.
Renal pathohistology
Renal tissue was analyzed by the light microscopy and
by the immunoflouorescence for c4d staining of the peri-
tubular capillaries. Pathohistological changes were clas-
sified according to the Banff 97 classification and its later
updates (Table 1).5,6
Urine cytology
Urine samples were collected within two days before
or after renal biopsy, but prior to any antirejection treat-
ment. Freshly voided urine samples were centrifuged for
5 min at 600 rpm in a cytocentrifuge. Air-dried sedi-
ments were fixed in cold acetone for 2 min followed by
washing in TBS (pH 7.6) for 1 min After that they were
incubated with primary anti-CD3 monoclonal antibody
(Dako) for 15 min at room temperature. After further
washing in TBS for 15 min, sediment was incubated with
streptavidin for 15 min, washed in TBS for 5 min, and
than incubated with chromogen for 4 min.
Statistical analysis
Statistica software version 7.1 (StatSoft, Tulsa, USA)
was used for statistical analysis. Medians and ranges
were used for continuous data that did not have normal
distribution. Differences between the groups were ana-
lyzed by the Fisher’s exact test for categorical data and
by the Mann-Whitney U-test for continuous and ordinal
data. p-value of <0.05 was considered to be statistically
significant.
Results
Patients characteristics are shown in Table 2. Among
total of 70 kidney biopsies there were 24 cases of AR,
while in 46 cases other pathohistological diagnosis was
obtained. Characteristics of patients with and without
AR are shown in Table 3.
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TABLE 1
BANFF CLASSIFICATION OF RENAL ALLOGRAFT REJECTION- BANFF 07 UPDATE
Normal
Antibody mediated changes
I. Acute tubular necrosis-like mediated changes




1. IA. Cases with significant interstitial in?ltration (>25% of parenchyma affected) and foci of moderate tubulitis
2. IB. Cases with significant interstitial in?ltration (>25% of parenchyma affected) and foci of severe tubulitis
3. IIA. Cases with mild-to-moderate intimal arteritis
4. IIB. Cases with severe intimal arteritis comprising >25% of the luminal area
5. III. Cases with 'transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with
accompanying lymphocytic inflammation
Other: Changes not considered to be due to rejection – acute and/or chronic
The distribution of cases in AR rejection group ac-
cording to the Banff classification was as follows: T-cell-
-mediated acute rejection in 23 cases (borderline 10,
grade IA 6, grade IB 5, grade IIA 1, grade III 1) and acute
antibody-mediated rejection in 1 case. There was no sta-
tistically significant difference between AR and non re-
jection patients regarding total HLA mismatch, as well
as regarding HLA-B and HLA-DR mismatch (p= n.s. for
all comparisons, Mann Whitney U test). In AR group
21% of the cases had CD3-positive cells in urine, whereas
in the non-rejecting group that percentage was 13 (p=
n.s., Fisher’s exact test). Specificity and sensitivity for es-
tablishing diagnosis of AR based on CD3 positive cells
(Figure 1) is shown in Table 4.
Exclusion of patients with borderline rejection from
the AR group did not influence results (data not shown).
Although CD3-positivity was associated with shorter
time after transplant, as compared with CD3-negative
cases in both groups, this did not reach statistical signifi-
cance. In AR group CD3-positivity occurred 30 (10–109)




Number of patients 56
Gender (m/f) 32/24
Age at transplant (years); median (range) 43 (16–69)
HLA mismatch; median (range) 3 (0–6)
HLA-B MM 1 (0–2)











CHARACTERISTICS OF AR AND NON-REJECTING GROUP
AR no rejection
Number of patients 23 33
Gender (m/f) 14/9 18/15
Age at transplant (years) mean (range) 46 (16–67) 42 (26–69)
Time of first biopsy after Tx (days) 59 (10–698) 97 (2–1071)
HLA mismatch of patients; median (range) 4 (1–6) 3 (0–6)
HLA-B mismatch 1 (0–2) 1 (0–2)




Age of donor (years); median (range) 43 (18–71) 40 (17–73)
Cause of ESRD





Induction (ATG/daclizumab) 2/21 4/29
Maintenance (MPA/tacrolimus/ciklosporin/corticosteroids) 21/13/8/18 33/20/12/25
Fig. 1. CD3-positive lymphocytes in urine (LSAB, x1000).
days after transplantation, while CD3-negative cases
were 101 (12–698) days after transplantation (p=0.086,
Mann Whitney U-test). Similarly, in non-rejection group
CD3-positivity occurred 33 (9–366) days after transplan-
tation and CD3-negative samples were 106 (2–1071) days
after transplantation (p=0.313, MannWhitney U test).
Discussion
Kidney transplant patients who suffer from AR are at
increased risk for decreased graft function and graft
loss.13,15 However, early detection and treatment of AR
has been shown to decrease renal allograft injury, leading
to non- -inferior long-term graft survival, if after an AR
episode renal function returned to the baseline value.15
Although it is highly sensitive and specific, renal biopsy
is invasive, and it is impractical to perform it frequently
due to associated inconvenience, morbidity and cost.4,16
To overcome these limitations of allograft biopsy many
attempts have been made to establish surrogate markers
for AR. However, none of these new biomarkers have
made their way into clinical practice as a universally ac-
cepted diagnostic tool, because of inferior performance in
comparison to biopsy.8
Native urine cytology was previously shown to detect
an increased frequency of lymphocytes and monocytes in
urine during AR17–19. However, it has been abandoned as
a screening method for AR, because it showed poor sen-
siivity and specificity11. An improved performance was
achieved by employing urine immunocytology with iden-
tification of different subpopulations of lymphocytes in
urine. Since it has been reported that 30–50% of cells
that infiltrate the kidney during AR are CD3-positive
lymphocytes, with intratubular infiltration (tubulitis) as
a hallmark, several studies have been published on the
performance of urine immunocytology for CD3 in diag-
nosing AR. Some of the previous studies showed sensitiv-
ity and specificity for that method of 79–87% and 95–
97%, respectively.7,11 Authors of these studies proposed
that method as a fast, simple and non-invasive procedure
that allows easy follow up of transplanted patients.
Based on these results we started immune monitoring
program of kidney transplant recipients based on uri-
nary cytology and immunocytochemistry at our center.
However, in our cohort of patients with transplanted kid-
ney or kidney and pancreas, sensitivity of only 21% with
specificity of 87% of CD3 staining of urinary lymphocytes
for diagnosis of AR was observed. From these results it is
evident that presence of CD3 lymphocytes in urine may
not correlate well with AR based on Banff criteria. Our
results are different from those in other reported studi-
es.7,11 Reasons for that discrepancy are unknown but
maybe attributed to several technical factors, besides the
possibility that urinary immunocytology for CD3 cells is
in fact insufficiently sensitive. Key technical issue that
might have contributed to lower sensitivity in our study
was somewhat different processing of urine for immuno-
cytological staining, using smaller urine volume, than in
some other reported studies. However, increased urine
volume would probably further decrease specificity of
CD3 staining for diagnosis of AR. Namely, it has been re-
ported that CD3-positive lymphocytes can be present in
urine even in normal graft during the first week after
transplantation, due to ischemia-reperfusion injury, as-
sociated with transplant procedure, which could con-
tribte to a decreased specificity.7 Although in our study
there was similarly a clear trend that patients with
CD3-positive cells without AR were earlier after trans-
plantation than those with negative CD3 cells in urine,
CD3-positivity occurred well after the first week after
transplantation. Another reason for a low specificity may
result from urinary infections, which may also be associ-
ated with findings of CD3-positive lymphocytes in urine.7
That was, however, not a case in our study, as there were
no patients with active urinary infection included in the
study. Thus, relatively low specificity of urinary CD3
staining is probably intrinsic limitation of the test. At-
tempts to increase performance of urine immunocyto-
logy consist of inclusion of more markers, such as a panel
of three or more antibodies for specific subpopulations of
T lymphocytes. A recent study reported highly increased
sensitivity and specificity with such approach.11 It may
also prove that a combination of urine lymphocyte subset
analysis with some of the recently investigated urinary
biomarkers, such as perforin, granzyme B, or FOXP3,
among the others, would demonstrate sufficient diagnos-
tic and prognostic value in kidney transplant patients
with AR20–22. However, further prospective studies are
necessary to confirm this.
An interesting side finding in our study is a lack of
associatian of HLA mismatch with occurrence of AR.
This probably reflects diminished significance of HLA
matching in face of modern immunosupression and fur-
ther justifies our approach to kidney transplantation by
not absolutely observing histocompatibility, especially in
living donor kidney transplantation.
Conclusion
Based on our results, early enthusiasm about using
urine cytology to diagnose AR seems unjustified, espe-
cially because of insufficient sensitivity of urine immu-
nocytology. While it is vital to achieve high sensitivity,
somewhat lower specificity may not represent a problem
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TABLE 4
SENSITIVITY, SPECIFICITY AND POSITIVE AND NEGATIVE PREDICTIVE VALUE OF CD-3 POSITIVITY OF URINARY LYMPHOCYTES
FOR DIAGNOSIS OF AR
Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
CD3-positive cells 21 87 45 68
in screening purposes. In that case finding of CD3-posi-
tive cells (or other biomarker) in urine should lead to re-
nal biopsy, if urinary infection is excluded. Kidney biopsy
remains gold standard for detection of AR. Urine immu-
nocytology may have potential to become one of the
screening methods for detection of AR in kidney trans-
plant patients, if substantial improvements in sensitivity
of this method could be made.
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IMUNOCITOLOGIJA URINA KAO NEINVAZIVNI DIJAGNOSTI^KI POSTUPAK ZA OTKRIVANJE
AKUTNOG ODBACIVANJA BUBREGA: ISKUSTVO KB »MERKUR«
S A @ E T A K
Biopsija bubrega je zlatni standard za postavljanje dijagnoze akutnog odbacivanja bubrega u transplantaciji bu-
brega. Zbog svoje invazivnosti, biopsija bubrega ima kontraindikacije i zna~ajne nuspojave. Pronalazak neinvazivne
metode za dijagnosticiranje akutnog odbacivanja unaprijedilo bi pra}enje transplantiranih pacijenata. Cilj ove studije je
bio procjena pouzdanosti immunocitologije urina na T-limfocite,u usporedbi sa biopsijom bubrega, u postavljanju dijag-
noze akutnog odbacivanja u pacijenta s transplantiranim bubregom. U ovu prospektivnu studiju uklju~eno je 56 paci-
jenata s transplantiranim bubregom ili bubregom i gu{tera~om. Pacijenti su ili transplantirani u Klini~koj bolnici
»Merkur«, ili su samo pra}eni u Klini~koj bolnici »Merkur« nakon transplantacije u drugoj bolnici. Pacijentima su
ra|ene protokol ili indikacijske biopsije (ukupno 70 biopsija) uz istovremenu imunocitologiju urina (odre|ivanje CD3-
-pozitivnih stanica u sedimentu urina). Akutno odbacivanje je na|eno u 24 biopsije. 23 epizode odbacivanja su bile
T-stani~no posredovane (6 stupanj IA, 5 stupanj IB, 1 stupanj IIA, 1 stupanj III i grani~no 10 epizoda), dok je u jednom
slu~aju dijagnosticirano akutno humoralno odbacivanje. U 46 biopti~kih uzoraka nije dijagnosticirano akutno odbaci-
vanje. CD-3 pozitivne stanice su na|ene u 21% slu~ajeva s prisutnim akutnim odbacivanjem u biopsiji, dok je u skupini
bez akutnog odbacivanja taj pozivitet je bio 13% (n.s.). Pronalazak CD-3 pozitivnih stanica u urinu imalo je osjetljivost
od 21%, specifi~nost od 87%, pozitivnu prediktivnu vrijednost od 45% i negativnu prediktivnu vrijednost od 68% za
dijagnozu akutnog odbacivanja. Iako je tubulitis zna~ajka akutnog odbacivanja posredovanog T-stanicama, detekcija
CD-3 pozitivih stanica u sedimentu urina pokazala je nedostatnu osjetljivost i specifi~nost za dokazivanje akutnog
odbacivanja u na{oj kohorti pacijenata sa transplantiranim bubregom.
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